Lantern Pharma's RADR® Surpasses 60 Billion Data Points, Targeting 100 Billion in 2024

Lantern Pharma Inc., a pioneer in AI-driven cancer drug discovery and development, marked significant milestones in the evolution of RADR®, its proprietary AI platform designed to revolutionize oncology drug development. CEO Panna Sharma highlighted the platform's exponential growth, with RADR® now surpassing 60 billion data points. This expansion promises enhanced precision and efficiency in cancer therapy innovation. With plans to exceed 100 billion data points in 2024, Lantern Pharma is poised to lead transformative advancements in adult and pediatric cancer treatment.